Deepa Purushothaman, MD
About
Titles
Postdoctoral Associate
Early Detection and Assessment Co-ordinator , Psychiatry - STEP program
Biography
Dr. Deepa Purushothaman is a Post-Doctoral Associate in the Department of Psychiatry at Yale School of Medicine. She works at the STEP (Specialized Treatment Early in Psychosis) program and is the Early Detection and Assessment Co-Ordinator (EDAC) for DMHAS region 5. She holds an MD in Psychiatry and Post-Doctoral fellowship in Schizophrenia from the National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India. Dr.Deepa’s clinical experience is in general adult psychiatry, with a year of focused work in Schizophrenia spectrum disorders. Her published research focuses on social cognitive deficits in Schizophrenia and novel treatments to address the same. Her academic interests also include history of Psychiatry, phenomenology of delusions, and early stages of psychosis including prodrome.
Appointments
Psychiatry
Postdoctoral AssociatePrimary
Other Departments & Organizations
- Psychiatry
- Specialized Treatment for Early Psychosis (STEP) Program
Education & Training
- Non Degree Program
- National Institute of Mental health and Neurosciences (NIMHANS), Post Doctoral Fellowship in Schizophrenia (2020)
- MD
- National Institute of Mental Health and Neurosciences (NIMHANS), Psychiatry (2019)
Research
Overview
Medical Research Interests
- View Lab Website
Specialized Treatment Early In Psychosis (STEP)
Research at a Glance
Publications Timeline
Publications
2023
Thymoma and Anti-GAD65 Antibody Positivity in Schizoaffective Disorder.
Sanahan R, Purushothaman D, Arshad F, Dahale AB. Thymoma and Anti-GAD65 Antibody Positivity in Schizoaffective Disorder. Prim Care Companion CNS Disord 2023, 25 PMID: 36821762, DOI: 10.4088/PCC.22cr03341.Peer-Reviewed Case Reports and Technical Notes
2021
Risk-mitigation measures in a tertiary care psychiatric hospital during COVID-19 pandemic.
Gowda GS, Ganjekar S, Dinakaran D, Philip S, Chithra NK, Purushothaman D, Shankarappa VH, Jaisoorya TS, Sivakumar PT, Nagabhusana SH, Singh VK, Kesavan M, Bhadrinarayan V, Murthy P, Gangadhar BN. Risk-mitigation measures in a tertiary care psychiatric hospital during COVID-19 pandemic. Indian J Psychiatry 2021, 63: 406-408. PMID: 34456359, DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_20_21.Peer-Reviewed Original ResearchThe dilemma of self vs others' interest: Altruistic behaviour in schizophrenia and the role of vasopressin.
Purushothaman D, Jacob AA, Kumar V, Varambally S, Venkatasubramanian G, Rao NP. The dilemma of self vs others' interest: Altruistic behaviour in schizophrenia and the role of vasopressin. Schizophr Res 2021, 230: 77-78. PMID: 33711680, DOI: 10.1016/j.schres.2021.02.005.Peer-Reviewed Original ResearchExperiential account of risk mitigation strategies in a tertiary care psychiatric setting during COVID-19 pandemic.
Ganjekar S, Gowda GS, Dinakaran D, Philip S, Chithra NK, Purushothaman D, Shankarappa VH, Sivakumar PT, Jaisoorya TS, Nagabhusana SH, Singh VK, Kesavan M, Bhadrinarayan V, Murthy P, Gangadhar BN. Experiential account of risk mitigation strategies in a tertiary care psychiatric setting during COVID-19 pandemic. Asian J Psychiatr 2021, 56: 102556. PMID: 33476994, DOI: 10.1016/j.ajp.2021.102556.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2020
"To co-operate or not?" Risky co-operative behavior in Schizophrenia and the effect of vasopressin.
Purushothaman D, Jacob A, Kumar V, Varambally S, Venkatasubramanian G, Rao NP. "To co-operate or not?" Risky co-operative behavior in Schizophrenia and the effect of vasopressin. Schizophr Res 2020, 222: 153-159. PMID: 32605809, DOI: 10.1016/j.schres.2020.06.013.Peer-Reviewed Original Research
2013
The history of parkinsonism: descriptions in ancient Indian medical literature.
Ovallath S, Deepa P. The history of parkinsonism: descriptions in ancient Indian medical literature. Mov Disord 2013, 28: 566-8. PMID: 23483637, DOI: 10.1002/mds.25420.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
Academic Achievements & Community Involvement
activity Effect of intranasal Vasopressin in altruistic behavior in Schizophrenia
Oral PresentationSIRS 2019 CongressDetails04/10/2019 - 04/14/2019Orlando, FL, United StatesCollaborators- Naren P RaoNational Institute of Mental health and Neurosciences
- Ganeshan VenkatasubrahmanianNational Institute of Mental health and Neurosciences
- Shivarama VaramballyNational Institute of Mental health and Neurosciences
- Vijayakumar KNational Institute of Mental health and neurosciences
- Bhargavi NagendraNational Institute of Mental health and Neurosciences
- Arpitha JacobNational Institute of mental health and Neurosciences
Abstract/Synopsisackground Increased self-interest and/or distrust in others are reported as possible reasons for decreased cooperation in paranoia1. While a few studies have examined trust behavior in schizophrenia altruistic behavior is underexplored in Schizophrenia. Altruism characterized by decreased self-interest, an evolutionarily advantageous human quality, is critical for social cooperation. Recent studies in healthy humans have suggested vasopressin to play critical role in altruistic behavior2. However, the effect of vasopressin on altruistic behavior in SCZ is not examined till date. In this study we examined the effect of vasopressin on altruistic behavior in schizophrenia using a neuroeconomics paradigm, dictator game. Methods 30 patients with DSM IV TR SCZ (age 32.73 ± 6.66; M:F = 16:14) and 30 matched healthy volunteers (HV) (age 31.23 ± 5.48;M:F= 17:13; p>0.05) participated in the study. Clinical severity was assessed using Scale for assessment of negative symptoms, scale for assessment of positive symptoms and Calgary depression rating scale. Childhood trauma was assessed using Adverse childhood experience (ACE)3 questionnaire. After clinical assessments, patients participated in a double blinded counterbalanced crossover study. Equal amount of vasopressin (40 IU) or saline placebo were administered to the patients. Participants were made to choose one from 5 Dictator game scenarios4,5 (of money units 150,180, 200, 210 and 210 each; allocation of funds varying in level of altruism). HV performed dictator game once without administration of vasopressin or placebo. We compared the performance of patients in placebo condition with that of HV using independent t-test. Effect of vasopressin vs placebo in patients was examined using paired t-test. Relation between clinical variables and performance in dictator game was examined using Pearson’s correlation analysis. Results Patients with SCZ, compared to HV shared significantly lower money units in dictator game ((SCZ-43.67 ± 37.37; HV - 90.67±25.86; t=5.67; p<0.001). SCZ shared significantly higher money units with intranasal Vasopressin (54.67 ± 36.93) compared to placebo (43.67 ± 37.37; t=; p= 0.013). Mean change in money units shared with vasopressin had a trend level negative correlation with ACE questionnaire score (r= -0.37; p=0.046) suggesting those with higher childhood trauma had greater response to vasopressin. There was no relation with other clinical variables. Discussion To the best of our knowledge, this is the first study examining the effects of the prosocial neuropeptide Vasopressin on Dictator game behavior in Schizophrenia. The results suggest that patients with SCZ have lower altruistic behavior compared to HV which improved partially with intranasal vasopressin. Whether the magnitude of improvement seen with single dose of vasopressin will increase with repeated doses need to be examined in systematic trials. The possible interaction between childhood adversity and response to vasopressin need to be examined in future. Findings of the study provide rationale to examine potential utility of vasopressin or its’ analogues in the treatment of SCZ.
honor Young Investigator
National AwardSchizophrenia Research FoundationDetails08/31/2018Indiaactivity Risky co-operative behaviour in Schizophrenia: A neuroeconomic examination
Poster PresentationSOBP 2018Details05/10/2018 - 05/12/2018New York, NY, United StatesCollaborators- Naren P RaoNational Institute of Mental Health and Neurosciences
- Ganeshan venkatasubrahmanianNational Institute of Mental Health and Neurosciences
- Shivarama VaramballyNational Institute of Mental Health and Nerosciences
- Vijayakumar KNational Institute of Mental Health and Neurosciences
- Bhargavi NagendraNational Institute of Mental Health and Neurosciences